Cellular Mechanisms of Antidepressant Action
抗抑郁作用的细胞机制
基本信息
- 批准号:6892826
- 负责人:
- 金额:$ 34.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-05-07 至 2008-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The current proposal is aimed at understanding the mode of action of medications that are currently used to treat a variety of depression and anxiety-related disorders. Although selective serotonin reuptake inhibitors (SSRI) are the most commonly prescribed antidepressants and anxiolytics, their mechanisms of action, and particularly the reason for their delayed (4-6 weeks) onset of therapeutic effects, are largely unknown. The general hypothesis that we are proposing to test is that the increased hippocampal neurogenesis elicited by chronic antidepressants contributes to the behavioral effects of these drugs. We, and others, have shown that various chronic antidepressant treatments result in an increase in neurogenesis in the dentate gyrus of the hippocampus. We have also shown that a chronic antidepressant treatment decreases certain anxiety-related behavioral responses. Finally, we have developed two distinct manipulations (a genetic one and radiological one) that disrupt antidepressant-induced hippocampal neurogenesis and also suppress antidepressant-induced behavioral responses. The genetic manipulation is a deletion of the gene encoding the 5-HT1A receptor; the resulting knockout mice are insensitive to the effects of SSRIs such as fluoxetine on both neurogenesis and behavior. The radiological manipulation consists of an X-irradiation of an area of the mouse brain containing the hippocampus; such a treatment prevents the effect of fluoxetine on both neurogenesis and behavior. These two sets of findings strongly suggest that the induction of neurogenesis elicited by fluoxetine in the hippocampus contributes to the behavioral effects of fluoxetine. The following experiments are designed to test this hypothesis and to establish the functional significance of adult hippocampal neurogenesis.
1. We will test the hypothesis that activation of hippocampal 5-HTIA receptors mediates the effects of fiuoxetine on neurogenesis and behavior. To accomplish this goal, we will construct "rescue" mice that express 5-HT1A receptors only in the hippocampus.
2. We will test the hypothesis that an ablation of neuronal progenitors will suppress the effects of fluoxetine. Such a finding would open new therapeutic avenues based on the stimulation of hippocampal neurogenesis, for the treatment of depression-related disorders.
描述(由申请人提供):当前的建议旨在了解目前用于治疗各种抑郁症和焦虑症的药物的作用方式。尽管选择性5-羟色胺再摄取抑制剂(SSRI)是最常见的抗抑郁药和抗焦虑药,但它们的作用机理,尤其是其延迟(4-6周)治疗作用发作的原因,但在很大程度上是未知的。 我们提议测试的一般假设是,慢性抗抑郁药引起的海马神经发生增加有助于这些药物的行为作用。我们和其他人已经表明,各种慢性抗抑郁治疗导致海马齿状回的神经发生增加。我们还表明,慢性抗抑郁治疗会降低某些与焦虑相关的行为反应。最后,我们开发了两种不同的操纵(一种遗传性操纵和放射学),它们破坏了抗抑郁药诱导的海马神经发生,并抑制了抗抑郁药诱导的行为反应。遗传操作是编码5-HT1A受体的基因的缺失。所得的基因敲除小鼠对SSRI(例如氟西汀对神经发生和行为)的影响不敏感。放射学操作由含有海马的小鼠大脑区域的X辐照组成。这种治疗可以阻止氟西汀对神经发生和行为的影响。这两组发现强烈表明,氟西汀在海马中引起的神经发生诱导有助于氟西汀的行为影响。以下实验旨在检验这一假设并建立成年海马神经发生的功能意义。
1。我们将测试以下假设:海马5-HTIA受体的激活介导硫西汀对神经发生和行为的影响。为了实现这一目标,我们将构建仅在海马中表达5-HT1A受体的“救援”小鼠。
2。我们将检验以下假设:神经祖细胞的消融将抑制氟西汀的作用。 这样的发现将基于海马神经发生的刺激开放新的治疗途径,以治疗与抑郁症相关的疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
Rene Hen的其他基金
THE ORIGIN AND FUNCTION OF SENSORY CUE AND PLACE RESPONSES IN THE DENTATE GYRUS
齿状回感觉线索和位置反应的起源和功能
- 批准号:1062668010626680
- 财政年份:2022
- 资助金额:$ 34.97万$ 34.97万
- 项目类别:
Endogenous opioid system contributions to anti-depressant action
内源性阿片系统对抗抑郁作用的贡献
- 批准号:95206389520638
- 财政年份:2018
- 资助金额:$ 34.97万$ 34.97万
- 项目类别:
Animal Models of Suicide: Behavior, Neurobiological and Molecular Phenotypes
自杀动物模型:行为、神经生物学和分子表型
- 批准号:1040879410408794
- 财政年份:2013
- 资助金额:$ 34.97万$ 34.97万
- 项目类别:
Animal Models of Suicide: Behavior, Neurobiological and Molecular Phenotypes
自杀动物模型:行为、神经生物学和分子表型
- 批准号:1020736410207364
- 财政年份:2013
- 资助金额:$ 34.97万$ 34.97万
- 项目类别:
Cellular Mechanisms of Antidepressant Action
抗抑郁作用的细胞机制
- 批准号:80464238046423
- 财政年份:2003
- 资助金额:$ 34.97万$ 34.97万
- 项目类别:
Molecular Genetic Study of Fear and Anxiety
恐惧和焦虑的分子遗传学研究
- 批准号:68702106870210
- 财政年份:2003
- 资助金额:$ 34.97万$ 34.97万
- 项目类别:
Cellular Mechanisms of Antidepressant Action
抗抑郁作用的细胞机制
- 批准号:72186247218624
- 财政年份:2003
- 资助金额:$ 34.97万$ 34.97万
- 项目类别:
Circuits underlying overgeneralization
过度概括的电路
- 批准号:1058570610585706
- 财政年份:2003
- 资助金额:$ 34.97万$ 34.97万
- 项目类别:
相似国自然基金
抗抑郁药氟西汀对泥蚶受精的影响及其作用机理研究
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:面上项目
2种临床常用抗抑郁药对肠道菌群的影响研究
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:面上项目
2种临床常用抗抑郁药对肠道菌群的影响研究
- 批准号:32170064
- 批准年份:2021
- 资助金额:58.00 万元
- 项目类别:面上项目
多脑区跨膜蛋白质组学技术用于抗抑郁潜在药靶发现
- 批准号:32171439
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:面上项目
抗抑郁药氟西汀对泥蚶受精的影响及其作用机理研究
- 批准号:32172944
- 批准年份:2021
- 资助金额:58.00 万元
- 项目类别:面上项目
相似海外基金
Relapse risk after Discontinuation of Antidepressants during Pregnancy (R-DAP study)
怀孕期间停用抗抑郁药后复发的风险(R-DAP 研究)
- 批准号:1056904410569044
- 财政年份:2020
- 资助金额:$ 34.97万$ 34.97万
- 项目类别:
Relapse risk after Discontinuation of Antidepressants during Pregnancy (R-DAP study)
怀孕期间停用抗抑郁药后复发的风险(R-DAP 研究)
- 批准号:1011728510117285
- 财政年份:2020
- 资助金额:$ 34.97万$ 34.97万
- 项目类别:
Relapse risk after Discontinuation of Antidepressants during Pregnancy (R-DAP study)
怀孕期间停用抗抑郁药后复发的风险(R-DAP 研究)
- 批准号:1033449910334499
- 财政年份:2020
- 资助金额:$ 34.97万$ 34.97万
- 项目类别:
Maternal exposure to antidepressants and psychiatric outcomes among offspring in a national birth cohort.
全国出生队列中母亲接触抗抑郁药物和后代的精神病结果。
- 批准号:1030801810308018
- 财政年份:2018
- 资助金额:$ 34.97万$ 34.97万
- 项目类别:
Maternal exposure to antidepressants and psychiatric outcomes among offspring in a national birth cohort.
全国出生队列中母亲接触抗抑郁药物和后代的精神病结果。
- 批准号:1005368510053685
- 财政年份:2018
- 资助金额:$ 34.97万$ 34.97万
- 项目类别: